acomplia in A Sentence

Acomplia was studied in America for two years.

Acomplia- what is your personal opinion?

Anyway, you can finish taking Acomplia any time you want.

Acomplia, along with CB1 receptors, reduces the EC system's over-activity.

Sanofi argues that Acomplia can also prevent the risk of cardiovascular disease.

Mind you, Piomelli has nothing against Acomplia- in fact, he's a fan.

In October 2008, Acomplia pills had lost their license all over the Europe.

The French-based company, the third-largest drug manufacturer in the world, has been developing Acomplia since 1992.

Acomplia was also persuaded by Sanofy as a disease that can stop the beginning of cardiovascular disease.

Go on to the next page to find out how these effects of Acomplia can help you.

Rimonabant/ Acomplia is said to have reduced the overall body fat by 10% in one out of three users.

That, too, is typical: Evidently, those who want the full benefits of Acomplia will probably have to take it indefinitely.

If Acomplia reverses the munchies, might it not also agitate the mind, roil the stomach, and increase sensitivity to pain?

In another study, stiff doses of Acomplia were given to least shrews(mouselike creatures), which caused them to vomit like nobody's business.

Australian scientists have found that rats treated with Acomplia are more sensitive when you jab their skin or apply heat to their tails.

But it was a 2-year trial on more than 1,500 obese or overweight Europeans and Americans that established Acomplia as a potential superstar.

A spokesman for Sanofi-Aventis says the company reserves its right to exercise"all of our options" in order to"educate" the public about Acomplia.

And quitters who used Acomplia were less likely to take up smoking again after a year, even though they had stopped taking the drug.

Sanofi-aventis submitted a New Drug Application to the FDA, which in turn issued a non approvable letter for Acomplia for use in smoking cessation.

Here's what that means: The moment Acomplia is approved for smoking cessation and obesity, physicians can prescribe it off-label for just about anything they like.

But here's the catch: No one knows when, or even if, the Food and Drug Administration will approve Acomplia for use by the general public.

It's called Acomplia, and if it lives up to a fraction of its promise, you may actually have to decide whether or not to take it.

So far," says the scientist who, more than any other, is responsible for the discovery of the endocannabinoid system,"[Acomplia] seems to be quite free of dangers.".

This was doubtless very interesting to Huestis, who hopes someday to use Acomplia, or something like it, to help habitual marijuana users wean themselves off dope.

Now Sanofi-Aventis is suggesting that Acomplia could become"complementary to Lipitor," the cholesterol reducer that is more widely prescribed than any other pill in the United States;

VanOoyen had been trying to quit smoking for 17 years when he saw an ad in a West Virginia paper for a clinical trial of Acomplia and signed up.

And that is why nearly every medical expert interviewed for this story practically begged Men's Health to tell its readers,"If you don't need Acomplia for health reasons, don't take it.".

The majority of people who used Acomplia in clinical trials lost at least 5 percent of their body weight in a year, but almost no one lost much more than 10 percent.

But those analysts assumed that Acomplia would be used merely to treat some of the 60 million Americans who are obese, along with some of the 30 million or so smokers who would like to quit.

What's more, Acomplia could well be just the first of a whole new class of drugs that work by taking advantage of one of the most intriguing biological discoveries of the past 20 years: the endocannabinoid system.

Showing 1 to 30 of 31 results

acomplia in A Sentence

Acomplia was studied in America for two years.

Acomplia- what is your personal opinion?

Anyway, you can finish taking Acomplia any time you want.

Acomplia, along with CB1 receptors, reduces the EC system's over-activity.

Sanofi argues that Acomplia can also prevent the risk of cardiovascular disease.

Mind you, Piomelli has nothing against Acomplia- in fact, he's a fan.

In October 2008, Acomplia pills had lost their license all over the Europe.

The French-based company, the third-largest drug manufacturer in the world, has been developing Acomplia since 1992.

Acomplia was also persuaded by Sanofy as a disease that can stop the beginning of cardiovascular disease.

Go on to the next page to find out how these effects of Acomplia can help you.

Rimonabant/ Acomplia is said to have reduced the overall body fat by 10% in one out of three users.

That, too, is typical: Evidently, those who want the full benefits of Acomplia will probably have to take it indefinitely.

If Acomplia reverses the munchies, might it not also agitate the mind, roil the stomach, and increase sensitivity to pain?

In another study, stiff doses of Acomplia were given to least shrews(mouselike creatures), which caused them to vomit like nobody's business.

Australian scientists have found that rats treated with Acomplia are more sensitive when you jab their skin or apply heat to their tails.

But it was a 2-year trial on more than 1,500 obese or overweight Europeans and Americans that established Acomplia as a potential superstar.

A spokesman for Sanofi-Aventis says the company reserves its right to exercise"all of our options" in order to"educate" the public about Acomplia.

And quitters who used Acomplia were less likely to take up smoking again after a year, even though they had stopped taking the drug.

Sanofi-aventis submitted a New Drug Application to the FDA, which in turn issued a non approvable letter for Acomplia for use in smoking cessation.

Here's what that means: The moment Acomplia is approved for smoking cessation and obesity, physicians can prescribe it off-label for just about anything they like.

But here's the catch: No one knows when, or even if, the Food and Drug Administration will approve Acomplia for use by the general public.

It's called Acomplia, and if it lives up to a fraction of its promise, you may actually have to decide whether or not to take it.

So far," says the scientist who, more than any other, is responsible for the discovery of the endocannabinoid system,"[Acomplia] seems to be quite free of dangers.".

This was doubtless very interesting to Huestis, who hopes someday to use Acomplia, or something like it, to help habitual marijuana users wean themselves off dope.

Now Sanofi-Aventis is suggesting that Acomplia could become"complementary to Lipitor," the cholesterol reducer that is more widely prescribed than any other pill in the United States;

VanOoyen had been trying to quit smoking for 17 years when he saw an ad in a West Virginia paper for a clinical trial of Acomplia and signed up.

And that is why nearly every medical expert interviewed for this story practically begged Men's Health to tell its readers,"If you don't need Acomplia for health reasons, don't take it.".

The majority of people who used Acomplia in clinical trials lost at least 5 percent of their body weight in a year, but almost no one lost much more than 10 percent.

But those analysts assumed that Acomplia would be used merely to treat some of the 60 million Americans who are obese, along with some of the 30 million or so smokers who would like to quit.

What's more, Acomplia could well be just the first of a whole new class of drugs that work by taking advantage of one of the most intriguing biological discoveries of the past 20 years: the endocannabinoid system.

Related Words

Related Words